Latest Samuel Lunenfeld Research Institute Stories

Internationally-respected Canadian researcher and founding CIHR president to fill prestigious advanced research leadership post TORONTO, Jan. 11, 2012 /PRNewswire/ - On behalf of the Board of the Canadian Institute for Advanced Research, David Dodge announced today the appointment of Dr. Alan Bernstein as the Institute's new President and CEO commencing May 1, 2012. "Alan is a visionary leader who has a wealth of experience guiding pioneering enterprises that conduct...

(Ivanhoe Newswire) "“ Scientists have discovered significant new insights into the causes of rheumatoid arthritis (RA) and other autoimmune disorders including type 1 diabetes, lupus and Graves disease.Dr. Katherine Siminovitch and her team identified the exact means by which an alteration in the gene PTPN22 increases risk for RA and other autoimmune disorders. The study used advanced genomics technologies that enable testing of millions of genetic markers in a single experiment to identify...

Findings will help lead to personalized therapies for common, complex illnesses characterized by abnormal immune responsesScientists at Mount Sinai Hospital, in collaboration with researchers at the University of Toronto, University Health Network and McGill University have obtained significant new insights into the causes of rheumatoid arthritis (RA) and other autoimmune disorders including type 1 diabetes, lupus and Graves disease.The findings represent a key initial step in realizing the...

Dr. François Robert and colleagues have accomplished a technical breakthroughThe research group of Dr. François Robert, a researcher at the Institut de recherches cliniques de Montréal (IRCM), in collaboration with the team of Dr. Daniel Durocher (Samuel Lunenfeld Research Institute and University of Toronto) accomplished a technical breakthrough: they mapped all the fragile sites of a living organism, the budding yeast Saccharomyces cerevisiae. The method used by the researchers can...

Researchers at the University of Toronto have identified a protein which plays a key role in the development of neurons, which could enhance our understanding of how the brain works, and how diseases such as Alzheimer's occur.U of T graduate student John Calarco, working in the labs of Prof. Ben Blencowe (Donnelly Centre for Cellular and Biomolecular Research, University of Toronto) and Prof. Mei Zhen (Samuel Lunenfeld Research Institute, Mount Sinai Hospital), has identified a protein known...

Miraculins Inc. (TSX VENTURE: MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs is pleased to announce that it has executed a license agreement with Mount Sinai Hospital ("MSH") to acquire the rights to commercialize a portfolio of biomarkers for use in developing diagnostic assays for the early detection of preeclampsia, a disease of growing incidence and the leading cause of maternal and prenatal deaths worldwide. A...

Miraculins Inc. (TSX VENTURE: MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs is pleased to announce that it has signed a term sheet with Mount Sinai Hospital to acquire a portfolio of biomarkers for use in developing diagnostic assays for the early detection of preeclampsia, a disease of growing incidence and the leading cause of maternal and prenatal deaths worldwide. Preeclampsia is a devastating disease of pregnancy...

A senior scientist at Mount Sinai Hospital has developed Canada's first two human embryonic stem cell lines, giving researchers across the country new potential and hope for eventually discovering treatments and cures for many chronic and fatal diseases. "My hope "“ and the hope of my world-class laboratory team "“ is that our step of developing the first Canadian embryonic stem cell lines will ultimately bring Canada and the world closer to treating or curing diseases such as...